Araris Biotech
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Riedhofstrasse 11, Zurich, Zurich, 8804,...Phone Number
+41 563104598Website
www.ararisbiotech.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Araris Biotech
Araris Biotech AG is a pioneering company specializing in the development of innovative antibody-drug conjugate (ADC) technologies, particularly through its proprietary linker platform that allows for efficient and stable payload attachment to antibodies. The company aims to create highly homogeneous and potent ADC therapies that specifically target cancer cells while minimizing damage to healthy tissues. Araris serves clients in the biopharmaceutical sector, focusing on partnerships with major pharmaceutical companies to advance next-generation ADCs. With a strong emphasis on research and development, Araris is positioned to make significant contributions to cancer treatment through its unique ADC technology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Araris Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Araris Biotech had a recent Job posting/layoffs
Earning: See what the market has to say on Araris Biotech recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Araris Biotech
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Araris Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Araris Biotech has new funding data
Check if Araris Biotech has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Araris Biotech launches new products
Check out if Araris Biotech is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Araris Biotech as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Araris Biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Araris Biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Araris Biotech.
Araris Biotech financials insights
Gather financial insights about Araris Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$16.8M
2022
Other Financing Round
$24M
Araris Biotech Tech Stack
A closer look at the technologies used by Araris Biotech
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Partnership
Partnership, Research & Development, Intellectual Property, Legal Affairs, Software, Medical Research, Pharmaceuticals
Funding
New Hire
Executive Move
Executive Moves, New Hire
Araris Biotech News & Media
Chugai and Araris Biotech AG Enter License Agreement for Araris' Linker-Payload ADC Technology AraLinQ®
TOKYO, JAPAN, February 10, 2026 /EINPresswire.com/ -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai") and Araris Biotech AG (hereafter "Araris") today announced that Chugai has exercised its option under the Research …Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technologyTaiho Pharmaceutical to Buy Araris Biotech for Initial $400M
By Daniella Parra Taiho Pharmaceutical said it will acquire Araris Biotech, a leader in antibody drug conjugates (ADCs), for an initial $400 million, with potential additional milestone payments of up to $740 million. Araris’ AraLinQ platform enhances ADC drug design, improving stability, safety, and anti-tumor effects, the company said. Its preclinical-stage ADC candidates for hematological […]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Araris Biotech
Sign Up For FreeTo access detailed company insights
Araris Biotech AG is a pioneering company specializing in the development of innovative antibody-drug conjugate (ADC) technologies, particularly through its proprietary linker platform that allows for efficient and stable payload attachment to antibodies. The company aims to create highly homogeneous and potent ADC therapies that specifically targe... Read More
